HTG Molecular Diagnostics Inc (NASDAQ:HTGM) price target set to $7.00 by HC Wainwright

ME Staff
-
0

Analyst Ratings For HTG Molecular Diagnostics Inc (NASDAQ:HTGM)

Today, HC Wainwright set its price target on HTG Molecular Diagnostics Inc (NASDAQ:HTGM) to $7.00 per share.

There are 3 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on HTG Molecular Diagnostics Inc (NASDAQ:HTGM) is Buy with a consensus target price of $7.00 per share, a potential 121.52% upside.

Some recent analyst ratings include

  • 7/9/2018-HTG Molecular Diagnostics Inc (NASDAQ:HTGM) had its Outperform rating reiterated by Leerink Swann

Recent Insider Trading Activity For HTG Molecular Diagnostics Inc (NASDAQ:HTGM)
HTG Molecular Diagnostics Inc (NASDAQ:HTGM) has insider ownership of 3.90% and institutional ownership of 36.16%.

  • On 12/1/2017 Shaun D Mcmeans, VP, sold 945 with an average share price of $2.11 per share and the total transaction amounting to $1,993.95.
  • On 11/1/2017 Shaun D Mcmeans, CFO, sold 945 with an average share price of $2.26 per share and the total transaction amounting to $2,135.70.
  • On 10/16/2017 Shaun D Mcmeans, VP, sold 946 with an average share price of $2.27 per share and the total transaction amounting to $2,147.42.
  • On 8/25/2017 Holdings A/S Novo, Major Shareholder, sold 1,149,813 with an average share price of $1.81 per share and the total transaction amounting to $2,081,161.53.
  • On 8/24/2017 Holdings A/S Novo, Major Shareholder, sold 382,437 with an average share price of $1.91 per share and the total transaction amounting to $730,454.67.
  • On 8/23/2017 Holdings A/S Novo, Major Shareholder, sold 47,162 with an average share price of $2.02 per share and the total transaction amounting to $95,267.24.
  • On 8/22/2017 Holdings A/S Novo, Major Shareholder, sold 80,586 with an average share price of $2.07 per share and the total transaction amounting to $166,813.02.

About HTG Molecular Diagnostics Inc (NASDAQ:HTGM)
HTG Molecular Diagnostics, Inc. develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq PATH Assay; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq EGFR, KRAS, and BRAF mutation assay; HTG EdgeSeq ALKPlus assay EU; and HTG EdgeSeq DLBCL cell of origin assay EU. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a collaboration agreement with Bristol-Myers Squibb for the development of custom RUO assays; master collaboration agreement with Merck KGaA; governing agreement with QIAGEN Manchester Limited; and development and professional services agreement with Invetech PTY Ltd. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.

Recent Trading Activity for HTG Molecular Diagnostics Inc (NASDAQ:HTGM)
Shares of HTG Molecular Diagnostics Inc closed the previous trading session at 3,16 −0,080 2,47 % with 3.26 shares trading hands.